NEKTAR THERAPEUTICS
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Nektar Therapeutics
Pharmaceutical Preparations, SIC 2834
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical enterprise focused on discovering and developing medicines in the field of immunotherapy. The company develops immunomodulatory agents engineered to selectively induce, amplify, attenuate, or prevent immune responses. Its pipeline focuses on treatments for autoimmune conditions and oncology, featuring therapeutic candidates such as rezpegaldesleukin and NKTR-0165/NKTR-0166 for autoimmune diseases, alongside NKTR-255 for cancer indications. Nektar primarily engages with global biopharmaceutical companies and partners through licensing, collaboration, and supply agreements.
The enterprise maintains research, development, and operational operations centered in the United States, with reportable geographical components spanning both domestic and international markets. The company conducts its corporate leadership and administrative operations from its principal executive offices located in San Francisco, California.
Summary of the business section of Nektar Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEKTAR THERAPEUTICS
- Founded
- 1990
- Headquarters
- San Francisco, CA
- Address
- 455 Mission Bay Boulevard South 94158
- Phone
- (415) 482-5300
- Website
- www.nektar.com
- Employees
- 63, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- NKTR
- Exchange
- Nasdaq
- IPO date
- Oct 31, 1997
- Shares outstanding
- 34M, Aug 7, 2026
- Public float
- $318.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Aug 8, 2025; 1-for-15 reverse, Jun 9, 2025; 2-for-1, Aug 23, 2000
- SEC CIK
- 906709
- CUSIP
- 640268306
- ISIN
- US6402683063
- LEI
- 5299005I24806IOIYE03
- EIN
- 94-3134940
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Howard W. Robin | President & CEO, Director | 54,655 |
| Jonathan Zalevsky | Chief R&D Officer | 9,570 |
| Linda M. Rubinstein | Interim CFO | – |
| Mark Andrew Wilson | Chief Legal Officer | 21,585 |
| Roy A. Whitfield | Director | 21,185 |
| Robert Chess | Director | 19,299 |
| Diana Brainard | Director | 3,904 |
| Jeffrey Robert Ajer | Director | 4,277 |
| R. Scott Greer | Director | 22,239 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Howard W. Robin | $6.26M | $14.14M | $1.22M | $17 | $125 |
| FY2024 Howard W. Robin | $3.76M | $5.35M | $1.12M | $5 | $93 |
| FY2023 Howard W. Robin | $3.14M | -$773.20K | $1.12M | $3 | $94 |
| FY2022 Howard W. Robin | $11.28M | -$8.74M | $3.09M | $13 | $90 |
| FY2021 Howard W. Robin | $11.15M | $8.03M | $4.38M | $79 | $100 |
| FY2020 Howard Robin | $11.24M | $6.46M | $4.38M | $79 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 63 employees, of which 39 employees were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 4, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 2, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 2, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 5, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 29, 2012 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 2, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 10, 2003 | Name change | Name changed from INHALE THERAPEUTIC SYSTEMS INC to NEKTAR THERAPEUTICS |
| May 14, 1998 | Name change | Name changed from INHALE THERAPEUTIC SYSTEMS to INHALE THERAPEUTIC SYSTEMS INC |
| Oct 31, 1997 | IPO | Initial public offering priced (424B4 prospectus) |